Nitroglycerin use in STEMI locations
Brenna Heaney1, Kaitlyn Zalar, Marlene Flores
1Brenna Heaney, Kaitlyn Zalar, Marlene Flores, and Sarah Jessee are students at Emory and Henry College in Marion, VA. Elyse Watkins is an associate professor and associate DMSc program director at Northeastern University in Boston, MA. E. Watkins serves as a JAAPA clinical editor. The authors have disclosed no other potential conflicts of interest, financial or otherwise.
Insights
Current guidelines advise against nitroglycerin for inferior ST-elevation myocardial infarction (STEMI). However, research indicates similar hypotension risks in inferior and non-inferior STEMI, suggesting protocol amendment for improved patient outcomes.
Area of Science:
- Cardiology
- Emergency Medicine
- Clinical Research
Background:
- Current acute coronary syndrome (ACS) protocols contraindicate nitroglycerin in inferior ST-elevation myocardial infarction (STEMI).
- This is due to concerns that nitroglycerin's preload-reducing effects could cause detrimental hypotension in these patients.
- Existing research suggests nitroglycerin-induced hypotension occurs at similar rates across different STEMI locations.
Purpose of the Study:
- To evaluate the necessity of current contraindications for nitroglycerin in inferior STEMI.
- To determine if nitroglycerin administration could benefit patients with inferior STEMI.
- To advocate for protocol amendments based on evidence regarding nitroglycerin's safety and efficacy.
Main Methods:
- Review of existing research and clinical data on nitroglycerin use in STEMI patients.
- Comparative analysis of hypotension rates in inferior STEMI versus non-inferior STEMI.
- Assessment of nitroglycerin's impact on myocardial function and patient outcomes.
Main Results:
- Nitroglycerin-induced hypotension rates are comparable between inferior and non-inferior STEMI.
- Hypotension development is linked to individual patient factors, not solely the infarct location.
- Nitroglycerin may offer benefits in preserving myocardial function.
Conclusions:
- Current ACS protocols regarding nitroglycerin for inferior STEMI require amendment.
- Removing the contraindication could improve therapeutic options and patient survival.
- Evidence supports reconsidering nitroglycerin's role in managing inferior STEMI.
Abstract:
Current acute coronary syndrome (ACS) protocols recommend against the administration of nitroglycerin to patients with inferior ST-elevation myocardial infarction (STEMI). Due to nitroglycerin's vasodilatory effects, which decrease preload and cardiac output, protocols warn of a possible critical drop in blood pressure with the drug's use that could be detrimental to patients with inferior STEMI. Research has shown, however, that nitroglycerin-induced hypotension occurs at similar rates in both inferior STEMI and non-inferior STEMI. Rather than the location of the culprit lesion, the development of hypotension depends on individual patient epidemiologic factors. An amendment to current ACS protocols for patients with inferior STEMI is warranted to reflect nitroglycerin's benefits in the preservation of myocardial function. Removing this barrier to the care of inferior STEMI would lead to therapeutic relief and improve patient survival overall.
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:18Drug Delivery: Enteral Route
Drugs in...
01:30Acute Coronary Syndrome I: Introduction
01:26Angina IV: Management
01:20Angina V: Nursing Management